Plasma Endocannabinoid Levels in Patients with Ischemic Cerebrovascular Disease
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 17-009831
Sponsor Protocol Number: 17-009831
About this study
The purpose of this observational study is to describe how the human endocannabinoid system (ECS) responds to an ischemic stroke or transient ischemic attack and explore whether modulation of the ECS holds potential to serve as a therapeutic target for neuroprotective therapies.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria - Ischemic Stroke:
- Male and female adults age 18+ presenting with acute ischemic stroke or transient ischemic episode < 12 hours from symptom onset.
- NIHSS>2.
- Non-contrast CT head excludes the presence of primary intracerebral hemorrhage or subarachnoid hemorrhage.
Inclusion Criteria - Transient Ischemic Attack:
- Male and female adults age 18+ presenting with acute ischemic stroke or transient ischemic episode < 12 hours from symptom onset.
- ABCD2 score of ≥ 4.
- Non-contrast CT head excludes the presence of primary intracerebral hemorrhage or subarachnoid hemorrhage.
Exclusion Criteria:
- < 18 years of age.
- Active malignancy.
- Active endocarditis.
- Systemic inflammatory diseases, connective tissue disease, or hypercoagulable states.
- Vasculopathies (Moya-Moya, Susac’s syndrome, hereditary conditions).
- Patients with primary intracerebral hemorrhage.
- Patients with seizure on presentation.
- Actively pregnant.
- Considered by the investigator to have a condition that precludes safe participation in the study.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Eugene Scharf, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available